CM
DNLI icon

Castleark Management’s Denali Therapeutics DNLI Stock Holding History

Castleark Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-127,460
Closed -$3.91M – 293
2022
Q3 		$3.91M Buy
+127,460
New +$4.14M 0.22% 119
2021
Q4 		– Sell
-66,145
Closed -$3.34M – 339
2021
Q3 		$3.34M Buy
66,145
+37,105
+128% +$2.09M 0.13% 158
2021
Q2 		$2.28M Buy
+29,040
New +$1.8M 0.08% 187

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Castleark Management's DNLI Position: Q4 2022 in Review

Castleark Management sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 127,460 shares — an estimated $3.91M sold.

Castleark Management first reported a position in DNLI in Q2 2021 and held it in 3 quarters. The position peaked at $3.91M in Q3 2022. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Castleark Management reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Castleark Management sold 127,460 Denali Therapeutics shares in Q4 2022, an estimated $3.91M.
  • Castleark Management first reported a position in Denali Therapeutics in Q2 2021 and held it in 3 quarters.
  • Castleark Management's Denali Therapeutics position peaked at $3.91M in Q3 2022.
  • 197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Castleark Management's 13F filing for Q4 2022, filed 10 Feb 2023.